Am­gen’s stom­ach can­cer drug boosts sur­vival in Phase 3, but oc­u­lar side ef­fects leave ques­tions

Am­gen’s an­ti­body can­di­date has cleared a late-stage tri­al in cer­tain stom­ach can­cer pa­tients, but some side ef­fects were more prob­lem­at­ic than ex­pect­ed based on pre­vi­ous …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER